Accepted Manuscript

Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells

Silvia Ghezzi, Lynsay Cooper, Alicia Rubio, Isabel Pagani, Maria Rosaria Capobianchi, Giuseppe Ippolito, Julien Pelletier, Maria Cecilia Z. Meneghetti, Marcelo A. Lima, Mark A. Skidmore, Vania Broccoli, Edwin A. Yates, Elisa Vicenzi

PII: S0166-3542(16)30659-3

DOI: 10.1016/j.antiviral.2016.12.023

Reference: AVR 3977

To appear in: Antiviral Research

Received Date: 3 November 2016

Revised Date: 22 December 2016

Accepted Date: 29 December 2016

Please cite this article as: Ghezzi, S., Cooper, L., Rubio, A., Pagani, I., Capobianchi, M.R., Ippolito, G., Pelletier, J., Meneghetti, M.C.Z., Lima, M.A., Skidmore, M.A., Broccoli, V., Yates, E.A., Vicenzi, E., Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells, *Antiviral Research* (2017), doi: 10.1016/j.antiviral.2016.12.023.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Heparin prevents Zika Virus induced-cytopathic effects in human neural progenitor cells

Silvia Ghezzi¹, Lynsay Cooper², Alicia Rubio¹, Isabel Pagani¹, Maria Rosaria Capobianchi³,

Giuseppe Ippolito³, Julien Pelletier^{2,4}, Maria Cecilia Z Meneghetti⁵, Marcelo A Lima^{5,6}, Mark A

Skidmore^{2,6}, Vania Broccoli^{7*}, Edwin A Yates^{6,5,2*‡} and Elisa Vicenzi^{1*}

¹San Raffaele Scientific Institute, Via Olgettina, Milano 20132 Italy;

²School of Life Sciences, Keele University, Keele, Staffordshire, ST5 5BG UK;

³["]Lazzaro Spallanzani" National Institute for Infectious Diseases, Rome, Italy;

⁴Instituto de Biotecnologia, Universidade Estadual Paulista Júlio de Mesquito Filho, Botucatu, SP, 18607-440 Brazil;

⁵Department of Biochemistry, UNIFESP, Rua Três de Maio, Vila Clementino, São Paulo, SP 04044-020 Brazil;

⁶Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool L69, 7ZB UK;

⁷National Research Council (CNR), Institute of Neuroscience, Milan, Italy.

*These authors contributed equally to this work.

[‡]Corresponding author: eayates@liv.ac.uk

Key words: Zika virus (ZIKV); neural progenitor cells; heparin; cell death

Zika virus (ZIKV) is a member of the *Flaviviridea* family comprising *ca*. 70 viruses sharing common structural features, and takes its name from the Zika Forest in Uganda where it was first isolated (Dick, 1953; Dick et al., 1952). It is the causative agent of an emerging infection arising from bites of the *Aedes aegypti* species for which, as yet, the full implications for human health remain unclear. Widespread infection and serious birth defects, including neurological diseases and microcephaly in Brazil have been reported (Rasmussen et al., 2016). In adults, ZIKV infection has been epidemiologically linked to increased prevalence of Guillain-Barré Syndrome (Cao-Lormeau et al., 2016; Parra et al., 2016). Thus, both *in utero* and adult, ZIKV-associated pathological conditions suggest that the virus could infect nerves (Bell et al., 1971) and neural cells (Garcez et al., 2016). Additional modes of transmission to mosquito bites have also emerged, including sexual transmission (D'Ortenzio et al., 2016; Foy et al., 2011; Musso et al., 2015) and blood transfusion (Motta et al., 2016). These could further expand the epidemic impact of ZIKV infection, increasing the need for an effective vaccine, and antiviral agents with which to treat infected individuals.

Conventional antiviral drug-discovery pipelines involve complex, expensive, and timeconsuming processes, militating against their rapid and widespread deployment, particularly in developing countries. One attractive alternative for combating emerging and rapidly spreading infectious diseases is drug repurposing (Cheng et al., 2016), the application of an existing licensed pharmaceutical agent for another medical need. This has already been proposed for the treatment of both hepatitis C (He et al., 2015) and Ebola virus (Sakurai et al., 2015) infections. Heparin, the widely used anticoagulant, has potentially attractive features including activity against attachment and entry of the enveloped viruses, human simplex (HSV) (Herold et al., 1996; Nahmias and Kibrick, 1964), human immunodeficiency (HIV) (Baba et al., 1988), SARS coronavirus (Vicenzi et al., 2004), and influenza (H5N1) (Skidmore et al., 2015). Here, we explore the effects of heparin on ZIKV infection in human neural progenitor cells (hNPCs) with particular regard to virus replication and induction of cytopathic effects resulting in cell death.

Cells:- Human neural progenitor cells (hNPCs) were obtained by the reprogramming of human adult skin fibroblasts (Movement Disorders Bio-Bank, Carlo Besta Institute, Milan, Italy) and were reprogrammed (CytoTune-iPS 2.0 Sendai Kit, Life Technologies) to obtain human induced pluripotent stem cells (hiPSCs), then maintained in feeder-free conditions (mTeSR1 culture medium, Stem Cell Technologies), as reported (Orellana et al., 2016). For embryoid bodies (EBs), dissociated hiPSCs were seeded into low-adhesion plates in mTeSR1 medium supplemented with N2 (1:200), ThermoFisher Scientific), human Noggin (0.5 μg/ml, R&D System), SB431542 (5 μM, Sigma), Y27632 (10 μM, Miltenyi Biotec) and penicillin-streptomycin (100 μg/ml, Sigma). For rosettes, EBs were plated after 10 days onto matrigel-coated plates (1:100, matrigel growth factor reduced, Corning) in DMEM/F12 (Sigma) with N2 (0.5%), non-essential amino acids (1%, ThermoFisher Scientific) and penicillin-streptomycin. After 10 days, cells were passaged with Accutase (Sigma) and seeded onto matrigel coated-flasks in media containing DMEM/F12, N2 (0.5%), B27 (0.5%), ThermoFisher Scientific), penicillin-streptomycin (1%) and basic fibroblast growth factor (FGF)2 (20 ng/ml, ThermoFisher Scientific).

Viruses:- The viruses employed were the historical ZIKV strain (MR766), (EVAg -European Virus Archive), or recent Brazilian strain (INMI-1; GenBank Accession # KU991811), isolated from an Italian citizen who had travelled in Brazil in January 2016. Both viral strains were expanded in Vero cells and titered in a Plaque Forming Assay (PFA) (Hamel et al., 2015).

Infection:- Cells were seeded at 3 x 10⁴ / ml in 48 well plates. After 3 days of culture, heparin (Celsus, Cincinnati) was added 1 h prior to infection at 100 µg/ml and then virus-containing supernatant was added, providing multiplicity of infection (moi) of 1. The efficiency of infection was evaluated by immunofluorescence staining with either an anti-flavivirus envelope monoclonal antibody (mAb) (Millipore, mAb 10216) or a double-stranded RNA (1:300, English and Scientific Consulting Kft, Hungary) 3 and 7 days post-infection. To

evaluate apoptosis, an Ab against cleaved-caspase-3 (1:200, Cell Signaling, 9661) was used. Cells were then washed with PBS and incubated for 1 h with Hoechst and either antimouse Alexa Fluor-488 or anti-rabbit Alexa Fluor-594 secondary Abs (1:1,000 in blocking solution, ThermoFisher Scientific). Viral supernatants were collected and viral titers were determined in the PFA. Cell death was detected in 10 µl samples of culture supernatant transferred into half-black 96 microwell plates (Costar). To each well, 50 µl of adenylate kinase detection reagent (ToxiLight[®] BioAssay, Lonza) was added and the plate incubated (10 min, room temperature). Luminescence was measured in a Mithras LB940 Microplate Reader (Berthold Technologies).

Immunofluorescence staining with Nestin (a neuroectodermal stem cell marker) and SOX2 (a transcription factor maintaining pluripotency or self-renewal) confirmed the nature of the hNPCs employed (**Figure 1A**, upper panels). hNPCs were incubated with heparin (100 µg/ml, 1 h prior to infection (see **Supplementary Table 1** for details of heparin characterization and ¹H and ¹³C NMR spectra in **Supplementary Figures 2** and **3**) with historical ZIKV strain MR766 and recent Brazilian strain, INMI-1. The proportion of MR766 infected hNPCs was *ca*. 60% (**Figures 1A**, middle panels). Modest decreases (not statistically significant) in infected cell numbers were observed in cultures pretreated with heparin. Progeny infectious virion production was measured in culture supernatants using standard PFA on Vero cells, indicating that heparin reduced the production of progeny virus by 2-3 fold (**Figure 1A**, lower panels).

We next evaluated the effect of heparin on hNPCs infection by the INMI-1 strain, which is characterized by lower virus replication efficiency (35%) than MR766. Nonetheless, the antiviral effect of heparin was modest and, as for MR766, not statistically different from untreated cultures, as determined by quantification of infection efficiency and viral titers released into the culture supernatant in the PFA on Vero cells (**Figure 1B**, lower panels).

Then, we analyzed the virus-induced cytopathic effects by measuring the levels of adenylate kinase released into the culture supernatant after damage of the cell membrane

(Crouch et al., 1993; Olsson et al., 1983). Heparin did not exert toxic effects on uninfected cells (**Figure 2**). Unexpectedly and strikingly, however, heparin fully prevented the virus-induced cytopathic effects of cultures infected with either the MR766 or INMI-1 ZIKV strains (**Figure 2A** and **B**, respectively). Thus, heparin partially uncoupled the virus replication (that was only modestly inhibited) from the virus-induced death of hNPCs.

ZIKV infection of cranial neural crest cells has been linked to the release of vascular endothelial growth factor (VEGF) and leukaemia inhibitory factor (LIF) exerting proapoptotic effects on adjacent cells (Bayless et al., 2016). Thus, we determined the proportion of cells that were positive for caspase-3 staining, as an indicator of apoptotic cell death (Lavrik, 2005). The proportion of caspase-3⁺ cells in uninfected and untreated cell cultures increased from 9.5 \pm 3.4% at day 3 after infection (day 6 after the initial seeding) to 29 \pm 1.1% 7 days after infection. At the same time points, heparin decreased the proportion of caspase-3⁺ cells to $5.9 \pm 2.7\%$ and $12.1 \pm 3.7\%$, respectively. In infected cultures, the proportion of caspase- 3^{+} cells increased to 31.1 ± 5.5% 7 days post-infection with the INMI-1 strain, and decreased to $16.2 \pm 0.3\%$ with heparin (data not shown). These results suggest that the activation of the master executor of apoptosis, i.e. caspase-3, is activated in hNPC cultures independently of virus infection and that heparin probably prevents its activation by stabilizing FGF2 for the duration of the culture, as reported (Caldwell et al., 2004). In contrast, heparin fully prevented virus-induced necrotic death of cells, as measured by the release of adenylate kinase in the culture supernatant (Figure 2), although the mechanism of action remains unknown. As the culture condition induced the apoptosis of uninfected hNPCs, we tested whether heparin affected ZIKV cytopathic effects, and in particular, prevented caspase-3 activation in Vero cells that are highly permissive to ZIKV replication. The background level of apoptosis in the absence of viral infection was negligible (Supplementary Figure 1). Indeed, heparin treatment did not alter the levels of viral replication as compared with control cells in Vero cells, however, it significantly decreased the percentage of caspase-3⁺ cells suggesting that heparin can also prevent ZIKV-induced apoptosis.

In terms of drug repurposing, in addition to caspase-3 inhibitors (Cheng et al., 2016; He et al., 2015), heparin represents both a clinically-approved pharmacological agent capable of preventing ZIKV-induced necrosis of neural cells, as observed with hNPCs, and a lead compound to help discover novel agents preventing virus replication and cytopathic effects.

Independently of the obvious heparin anticoagulant effect, there is now considerable evidence that heparin possesses anti-inflammatory, anti-apoptotic and proliferative activities that rely on a variety of mechanisms (Katsi et al., 2016). However, the polyanionic nature of heparin favours the neutralization of cationic mediators of inflammation and apoptosis but, also viral envelopes (Rusnati et al., 2009). The mechanism through which heparin derivatives inhibit infectivity in other viral infections, such as herpes simplex virus (Shukla and Spear, 2001), is most likely by competing with host cell surface glycoproteins or proteoglycans, or in other cases, through binding of low specificity to several proteins by virtue of their polyanionic nature (Skidmore et al., 2015). In the present case, however, the effect of heparin on infectivity is less striking than its ability to protect infected cells from cell death. The most likely mechanism to explain this phenomenon is that heparin is binding several proteins that promote inflammation and cell death. Heparin has been documented to bind and, in many cases neutralise, a range of relevant growth factors and enzymes, including tissue necrosis factor- α (TNF- α) (Salas et al., 2000; Spratte et al., 2013; Veraldi et al., 2015).

In conclusion, heparin is used safely during pregnancy and could serve as a potential adjunct therapy in the presence or likelihood of ZIKV infection. While ultra-low molecular weight heparin has been reported to cross the blood brain barrier (FDA guidelines, accessed 05/10/2016), heparin does not cross the placenta http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm219000.htm. Improved delivery systems may facilitate the administration of heparin and heparin derivatives.

MAL and EAY gratefully acknowledge Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) for financial support. MAS and EAY acknowledge the BBSRC/EPSRC for a New Investigator Award and Keele University for Seed Funding Award (MAS, EAY and MAL). Gl acknowledges the European Union, Seventh Framework Programme and European Union's Horizon 2020 Research and Innovation Programme.

REFERENCES

Baba, M., Pauwels, R., Balzarini, J., Arnout, J., Desmyter, J., De Clercq, E., 1988. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A 85, 6132-6136.

Bayless, N.L., Greenberg, R.S., Swigut, T., Wysocka, J., Blish, C.A., 2016. Zika Virus Infection Induces Cranial Neural Crest Cells to Produce Cytokines at Levels Detrimental for Neurogenesis. Cell Host Microbe 20, 423-428.

Bell, T.M., Field, E.J., Narang, H.K., 1971. Zika virus infection of the central nervous system of mice. Arch Gesamte Virusforsch 35, 183-193.

Caldwell, M.A., Garcion, E., terBorg, M.G., He, X., Svendsen, C.N., 2004. Heparin stabilizes FGF-2 and modulates striatal precursor cell behavior in response to EGF. Exp Neurol 188, 408-420.

Cao-Lormeau, V.M., Blake, A., Mons, S., Lastere, S., Roche, C., Vanhomwegen, J., Dub, T., Baudouin, L., Teissier, A., Larre, P., Vial, A.L., Decam, C., Choumet, V., Halstead, S.K., Willison, H.J., Musset, L., Manuguerra, J.C., Despres, P., Fournier, E., Mallet, H.P., Musso, D., Fontanet, A., Neil, J., Ghawche, F., 2016. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 387, 1531-1539.

Cheng, F., Murray, J.L., Rubin, D.H., 2016. Drug Repurposing: New Treatments for Zika Virus Infection? Trends Mol Med.

Crouch, S.P., Kozlowski, R., Slater, K.J., Fletcher, J., 1993. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J Immunol Methods 160, 81-88.

D'Ortenzio, E., Matheron, S., Yazdanpanah, Y., de Lamballerie, X., Hubert, B., Piorkowski, G., Maquart, M., Descamps, D., Damond, F., Leparc-Goffart, I., 2016. Evidence of Sexual Transmission of Zika Virus. N Engl J Med 374, 2195-2198.

Dick, G.W., 1953. Epidemiological notes on some viruses isolated in Uganda; Yellow fever, Rift Valley fever, Bwamba fever, West Nile, Mengo, Semliki forest, Bunyamwera, Ntaya, Uganda S and Zika viruses. Trans R Soc Trop Med Hyg 47, 13-48.

Dick, G.W., Kitchen, S.F., Haddow, A.J., 1952. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg 46, 509-520.

Foy, B.D., Kobylinski, K.C., Chilson Foy, J.L., Blitvich, B.J., Travassos da Rosa, A., Haddow, A.D., Lanciotti, R.S., Tesh, R.B., 2011. Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg Infect Dis 17, 880-882.

Garcez, P.P., Loiola, E.C., Madeiro da Costa, R., Higa, L.M., Trindade, P., Delvecchio, R., Nascimento, J.M., Brindeiro, R., Tanuri, A., Rehen, S.K., 2016. Zika virus impairs growth in human neurospheres and brain organoids. Science 352, 816-818.

Hamel, R., Dejarnac, O., Wichit, S., Ekchariyawat, P., Neyret, A., Luplertlop, N., Perera-Lecoin, M., Surasombatpattana, P., Talignani, L., Thomas, F., Cao-Lormeau, V.M., Choumet, V., Briant, L., Despres, P., Amara, A., Yssel, H., Misse, D., 2015. Biology of Zika Virus Infection in Human Skin Cells. J Virol 89, 8880-8896.

He, S., Lin, B., Chu, V., Hu, Z., Hu, X., Xiao, J., Wang, A.Q., Schweitzer, C.J., Li, Q., Imamura, M., Hiraga, N., Southall, N., Ferrer, M., Zheng, W., Chayama, K., Marugan, J.J., Liang, T.J., 2015. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Sci Transl Med 7, 282ra249.

Herold, B.C., Gerber, S.I., Belval, B.J., Siston, A.M., Shulman, N., 1996. Differences in the susceptibility of herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry. J Virol 70, 3461-3469.

Katsi, V., Kanellopoulou, T., Makris, T., Nihoyannopoulos, P., Nomikou, E., Tousoulis, D., 2016. Aspirin vs Heparin for the Prevention of Preeclampsia. Curr Hypertens Rep 18, 57.

Lavrik, I.N., 2005. Caspases: pharmacological manipulation of cell death. Journal of Clinical Investigation 115, 2665-2672.

Motta, I.J., Spencer, B.R., Cordeiro da Silva, S.G., Arruda, M.B., Dobbin, J.A., Gonzaga, Y.B., Arcuri, I.P., Tavares, R.C., Atta, E.H., Fernandes, R.F., Costa, D.A., Ribeiro, L.J., Limonte, F., Higa, L.M., Voloch, C.M., Brindeiro, R.M., Tanuri, A., Ferreira, O.C., Jr., 2016. Evidence for Transmission of Zika Virus by Platelet Transfusion. N Engl J Med 375, 1101-1103.

Musso, D., Roche, C., Robin, E., Nhan, T., Teissier, A., Cao-Lormeau, V.M., 2015. Potential sexual transmission of Zika virus. Emerg Infect Dis 21, 359-361.

Nahmias, A.J., Kibrick, S., 1964. Inhibitory effect of heparin on herpes simplex virus. J Bacteriol 87, 1060-1066.

Olsson, T., Gulliksson, H., Palmeborn, M., Bergstrom, K., Thore, A., 1983. Leakage of adenylate kinase from stored blood cells. J Appl Biochem 5, 437-445.

Orellana, D.I., Santambrogio, P., Rubio, A., Yekhlef, L., Cancellieri, C., Dusi, S., Giannelli, S.G., Venco, P., Mazzara, P.G., Cozzi, A., Ferrari, M., Garavaglia, B., Taverna, S., Tiranti, V., Broccoli, V., Levi, S., 2016. Coenzyme A corrects pathological defects in human neurons of PANK2-associated neurodegeneration. EMBO Mol Med 8, 1197-1211.

Parra, B., Lizarazo, J., Jiménez-Arango, J.A., Zea-Vera, A.F., González-Manrique, G., Vargas, J., Angarita, J.A., Zuñiga, G., Lopez-Gonzalez, R., Beltran, C.L., Rizcala, K.H., Morales, M.T., Pacheco, O., Ospina, M.L., Kumar, A., Cornblath, D.R., Muñoz, L.S., Osorio, L., Barreras, P., Pardo, C.A., 2016. Guillain–Barré Syndrome Associated with Zika Virus Infection in Colombia. New England Journal of Medicine 375, 1513-1523.

Rasmussen, S.A., Jamieson, D.J., Honein, M.A., Petersen, L.R., 2016. Zika Virus and Birth Defects--Reviewing the Evidence for Causality. N Engl J Med 374, 1981-1987.

Rusnati, M., Vicenzi, E., Donalisio, M., Oreste, P., Landolfo, S., Lembo, D., 2009. Sulfated K5 Escherichia coli polysaccharide derivatives: A novel class of candidate antiviral microbicides. Pharmacol Ther 123, 310-322.

Sakurai, Y., Kolokoltsov, A.A., Chen, C.C., Tidwell, M.W., Bauta, W.E., Klugbauer, N., Grimm, C., Wahl-Schott, C., Biel, M., Davey, R.A., 2015. Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment. Science 347, 995-998.

Salas, A., Sans, M., Soriano, A., Reverter, J.C., Anderson, D.C., Pique, J.M., Panes, J., 2000. Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism. Gut 47, 88-96.

Shukla, D., Spear, P.G., 2001. Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry. J Clin Invest 108, 503-510.

Skidmore, M.A., Kajaste-Rudnitski, A., Wells, N.M., Guimond, S.E., Rudd, T.R., Yates, E.A., Vicenzi, E., 2015. Inhibition of influenza H5N1 invasion by modified heparin derivatives. Med. Chem. Commun. 6, 640-646.

Spratte, J., Meyer zu Schwabedissen, H., Endlich, N., Zygmunt, M., Fluhr, H., 2013. Heparin inhibits TNF-alpha signaling in human endometrial stromal cells by interaction with NF-kappaB. Mol Hum Reprod 19, 227-236.

Veraldi, N., Hughes, A.J., Rudd, T.R., Thomas, H.B., Edwards, S.W., Hadfield, L., Skidmore, M.A., Siligardi, G., Cosentino, C., Shute, J.K., Naggi, A., Yates, E.A., 2015. Heparin

derivatives for the targeting of multiple activities in the inflammatory response. Carbohydr Polym 117, 400-407. Vicenzi, E., Canducci, F., Pinna, D., Mancini, N., Carletti, S., Lazzarin, A., Bordignon, C.,

Poli, G., Clementi, M., 2004. Coronaviridae and SARS-associated coronavirus strain HSR1. Emerg Infect Dis 10, 413-418.

Figure 1. Heparin does not inhibit ZIKV infection of hNPCs

A. Infection of hNPCs with the MR766 strain with (middle two panels) and without (upper two panels) heparin treatment (100 μ g/ml). To determine that the cells were *bona fide* hNPCs, cells were stained with Sox2 (red), Nestin (green) and Hoechst (blue). Uninfected and infected cells were fixed after 3 days with paraformaldehyde solution and stained with a mAb specific for Flavivirus E protein (green). After PBS washes, cells were washed again, mounted and examined by microscopy. Quantification of infection efficiency and viral titers released into the culture supernatant are reported in the two lower panels (left and right, respectively). Scale bar of upper left panel: 20 μ m, scale bar of remaining panels: 5 μ m. Bar graphs indicate the mean ± SEM of 4 independent experiments. P values were calculated by Student's paired t-test.


B. Infection of hNPCs by the INMI-1 strain, with (middle two panels) or without (upper panel) heparin treatment (100 μ g/ml). Uninfected and infected cells were fixed after 7 days with paraformaldehyde solution and stained with a mAb specific for Flavivirus E protein (green). Quantification of infection efficiency and viral titers released into the culture supernatant are reported in the lower two panels (left and right, respectively). Scale bar: 5 μ m. Bar graphs indicate the mean ± SEM of 2 fields including more than 1,000 cells in 3 independent experiments. P values were calculated by Student's paired t-test.

Figure 2. Heparin prevents virus-induced CPE

A. Supernatant of infected hNPCs with the MR766 strain was collected 3 days post infection.
The results are expressed as relative luminescent unit (RLU). Data are expressed as mean
± SEM of 3 independent experiments. Repeated measures Anova was used with the

Bonferroni correction. *Represents statistical comparison among groups (**, p<0.01; *, p<0.05). **B.** Supernatant of infected hNPCs with the INMI-1 strain was collected 7 days post infection. The cell death was analyzed as reported in **A**. Results are expressed as relative luminescent unit (RLU). Data represent the mean \pm SEM of 3 independent experiments. Repeated Measures ANOVA was used with the Bonferroni correction. *Represents statistical comparison among groups (**, p<0.01; *, p<0.05).

Figure 1



Infected (MR766)

Hoechst E protein

100-

80-


60-

40


20-

0.


% Virus+ cells/Hoechst




Nil



Heparin








Infected (INMI-1)


Nil

Heparin










Uninfected

Figure 2



Highlights

*Recent outbreak of Zika virus in Brazil included widespread neurological effects

[•]One approach to tackling emerging infection is to re-purpose existing pharmaceuticals

*The anticoagulant, heparin, inhibits infection weakly, but completely prevents cell death